UNCY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
UNCY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Unicycive Therapeutics's dividends per share for the three months ended in Sep. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Unicycive Therapeutics's Dividend Yield % is 0.00%.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Unicycive Therapeutics's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unicycive Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Dividends per Share | - | - | - | - | - |
Unicycive Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Dividends per Share | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Unicycive Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Unicycive Therapeutics's Dividend Yield % falls into.
Dividends paid to per common share.
Unicycive Therapeutics (NAS:UNCY) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Unicycive Therapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as
Dividend Payout Ratio | = | Dividends per Share (Q: Sep. 2024 ) | / | EPS without NRI (Q: Sep. 2024 ) |
= | 0 | / | -0.07 | |
= | N/A |
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Unicycive Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Sandeep Laumas | director | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
John L Ryan | director | C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016 |
Sara Kenkare-mitra | director | C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080 |
Gaurav Aggarwal | director | C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025 |
Douglas Jermasek | other: EVP of Corporate Strategy | 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022 |
Brigitte Schiller | director | UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022 |
John Townsend | officer: Chief Financial Officer | 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128 |
Pramod Gupta | officer: EVP, Pharmaceuticals and BD | UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022 |
Shalabh K. Gupta | director, officer: CEO | UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022 |
From GuruFocus
By Marketwired • 05-15-2024
By Marketwired • 04-10-2024
By GuruFocus News • 11-14-2024
By Marketwired • 07-01-2024
By Marketwired • 09-16-2024
By Marketwired • 07-10-2024
By Marketwired • 10-28-2024
By Marketwired • 07-11-2024
By Marketwired • 08-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.